Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cataract & MIGS cases in Montana: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 7% on average (255 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 35 | 10,038 | 21% |
| 2020 | 34 | 8,563 | 22% |
| 2021 | 33 | 8,913 | 25% |
| 2022 | 31 | 9,657 | 27% |
| 2023 | 32 | 10,464 | 30% |
| 2024 | 31 | 9,758 | 32% |
| 2025 from claims | – | 9,487 8,706–10,037 | 32% |
| 2026 forecast | – | 9,688 8,524–11,179 | 32% |
| 2027 forecast | – | 9,799 8,377–11,678 | 32% |
| 2028 forecast | – | 9,912 8,271–12,137 | 33% |
| 2029 forecast | – | 10,026 8,189–12,574 | 33% |
| 2030 forecast | – | 10,141 8,124–12,995 | 34% |
Cataract extraction with IOL, with and without glaucoma stents; the ASC volume engine. Professional codes (what the surgeon bills): CPT 66984, 66982, 66989, 66991, 66987, 66988, 65820, 66174, 66183, 0671T, 0449T.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 65% of the cases CMS names in Montana; 17 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 17% hospital outpatient, 83% surgery center. The share outside the hospital has moved +20 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 945 | 147,381−0.7%/yr | −0.7%/yr | 43.2 | 82% | 160,000 in 2030+1.4%/yr |
| Washington | 195 | 42,031−2.8%/yr | −2.8%/yr | 53.9 | 87% | 43,500 in 2030+0.6%/yr |
| Arizona | 159 | 41,851+0.2%/yr | +0.2%/yr | 55.5 | 97% | 45,100 in 2030+1.3%/yr |
| Colorado | 127 | 26,813−0.4%/yr | −0.4%/yr | 54.0 | 87% | 31,400 in 2030+2.7%/yr |
| Oregon | 132 | 19,5390%/yr | 0%/yr | 45.7 | 85% | 23,200 in 2030+2.9%/yr |
| Utah | 100 | 16,336−0.9%/yr | −0.9%/yr | 73.3 | 75% | 15,600 in 2030−0.8%/yr |
| Nevada | 55 | 13,217−6.7%/yr | −6.7%/yr | 45.1 | 98% | 14,000 in 2030+1%/yr |
| New Mexico | 34 | 9,620−3.6%/yr | −3.6%/yr | 41.1 | 92% | 10,700 in 2030+1.8%/yr |
| Idaho | 39 | 9,223+0.2%/yr | +0.2%/yr | 44.5 | 99% | 11,200 in 2030+3.3%/yr |
| Hawaii | 42 | 5,492−2.8%/yr | −2.8%/yr | 42.1 | 94% | 5,990 in 2030+1.4%/yr |
| Alaska | 17 | 3,008−6%/yr | −6%/yr | 25.0 | 85% | 3,720 in 2030+3.6%/yr |
| Wyoming | 5 | 1,991−3.7%/yr | −3.7%/yr | 18.2 | 92% | 2,190 in 2030+1.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Vitreoretinal surgery | 5 | 349−0.8%/yr | −0.8%/yr | 1.80.7× | 51% | 340 in 2030−0.3%/yr |
Cataract & MIGS in every state, and its device makers · Every procedure market in Montana · Every state · Compare with California
Alcon leads with 30% of company spending on these surgeons in 2025, −3 pts on 2024.
In 2025, 12 companies reported engagement with Montana’s surgeons worth $13K in consulting, speaking, meals and travel tied to these products, about $405 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.